Loading...
•
Sep 30, 2021
UroGen Q3 2021 Earnings Report
UroGen reported progress both clinically and commercially.
Key Takeaways
UroGen Pharma reported Q3 2021 financial results, with Jelmyto net product revenue of $11.4 million, representing over 200% growth compared to Q3 2020. The company is initiating a new single-arm Phase 3 study of UGN-102 and is pleased with the strong demand for Jelmyto.
Initiated a single-arm Phase 3 study for UGN-102 in low-grade, intermediate-risk, non-muscle invasive bladder cancer.
Jelmyto net product revenue reached $11.4 million for Q3 2021.
New patient starts in September and October outpaced July and August by nearly 60%.
706 sites have been activated as of November 1, 2021, representing a 73% increase since August 1, 2021.
Revenue by Segment
Forward Guidance
The Company is reducing its anticipated full year 2021 operating expenses to the range of $137 million to $142 million, from $155 million to $165 million, the new guidance includes non-cash share-based compensation expense of $22 to $25 million, subject to market conditions. In addition, the Company is providing full year 2021 revenue guidance of $47 million to $51 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...